← All companies

NGEN

NervGen Pharma Corp.

NGEN Nasdaq Pharmaceutical Preparations EDGAR ↗

$1.64

+0.04 +2.50%

Key statistics

from XBRL data in SEC filings

Market cap

$131M

Revenue (TTM)

—

Net income (TTM)

—

EPS (TTM)

—

P/E ratio

—

Dividend yield

—

Free cash flow

—

Cash

—

Total assets

—

Gross margin

—

52-week range

$1.58 – $6.30

Recent SEC filings

36 most recent

Annual, quarterly & current reports

6-K FORM 6-K Jul 2, 2026 6-K FORM 6-K Jun 1, 2026 6-K FORM 6-K May 26, 2026 6-K FORM 6-K May 22, 2026 6-K FORM 6-K May 18, 2026 6-K FORM 6-K May 15, 2026 6-K FORM 6-K Apr 27, 2026 40-F Mar 31, 2026 6-K FORM 6-K Mar 13, 2026 6-K FORM 6-K Feb 13, 2026 6-K FORM 6-K Feb 10, 2026 6-K FORM 6-K Jan 8, 2026

Other filings

SUPPL Jul 2, 2026 EFFECT May 26, 2026 SUPPL May 26, 2026 F-X FORM F-X May 26, 2026 F-10 May 26, 2026 SUPPL May 22, 2026 SUPPL May 21, 2026 S-8 FORM S-8 May 7, 2026 S-8 FORM S-8 Jan 23, 2026 EFFECT Jan 7, 2026 CERT Jan 7, 2026 8-A12B Jan 7, 2026 F-10/A Jan 7, 2026 F-X FORM F-X Dec 17, 2025 F-10 Dec 17, 2025 D Item 06b Dec 14, 2021 D/A Item 06b Aug 25, 2021 D Item 06b Aug 17, 2021 D/A Item 06b Jun 2, 2021 D Item 06b Aug 25, 2020 D Item 06b Jun 3, 2020 D Item 06b Nov 22, 2019 D Item 06b Mar 21, 2019 D Item 06b Sep 20, 2018